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  Thirty－seven cases of superficial bladder cancer were treated with 4’一epi－adriamycin （EPI）
by intravesical instiliation to investigate the optimal dosage and treatment schedule． PatSents
were randomized into either group A： 50 mg／day for 6 days （regimen A） or group B： 60 mgf
day for 3 days × 2 courses with 4 days interval （regimen B）． Seventeen cases were evaluated
in both groups， three cases were ineligible in group B． Patient characteristics such as age，
sex， size of tumor， stage and grade werc not signi丘cantly di既rcnt between the two groups．
Rcsponse rates were 41．2％．．（gro叩A）and 70．6％（group B）， while incidence of toxic量ty was
47．1％ and 50．0％ respectively． There is a trend in favor of regimen B which deserves to be
more extensively verified・



















（EPI 50 mg／生塩水30 ml， ADM膀胱腔内注入療
法呂・9）における至適注入濃度）での6日間連続注入法








た．B群にはEPI 60 mg．を生塩水30 mlに溶解
（2，000 Pt 9／ml）し，3日間連続注入し4日間休薬，そ
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Table 1． Patient characteristics of randomized study





   Tl
Grade Gl
   G2
   Gx
Tum。r Size（く1cm）
53－81（mean：67．5）
   16
   1
   9





43－87（mean： 66 ，． 1 ）
   18
   2
   10
   10
   3
   14
   3










    Totai 6 instillations
    Maintained for 2 hours
    Evaluated 2 weeks after the last
    instillation
Fig． 1． Treatment schedule of randomized









T18例であり， B群．TalO例， TI lO例であった．
また，病理組織学的悪性度ではA群 Gl 5例， G2




















CR 1例， PR 6例， NC lO例， PR以上の有効率









A 50mg 1 6 10
  （1600pg／ml） （41Z）





















Table 3． Adverse reactions of randomized
     study
Group A Group B







8 （47） 9 （45）
4 （24） 2 （10）
4 （24） 1 （ 5）




























































り，A群ではCR 1例， PR 6例， NC 10例，また，
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